Company Filing History:
Years Active: 2009
Title: Hikeaki Miyake: Innovator in Cancer Treatment
Introduction
Hikeaki Miyake is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on enhancing the effectiveness of chemotherapy and radiation therapy for cancer patients.
Latest Patents
Miyake holds a patent titled "Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides." This patent describes a method for administering antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene. The administration of these ODNs can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells. As a result, this method enhances the chemosensitivity of these cells to chemotherapy agents and radiation. For instance, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing them to both the agent and an ODN that reduces TRPM-2 levels. This innovative approach provides an improved method for treating renal cell cancer, which is typically resistant to conventional chemotherapy agents.
Career Highlights
Miyake is affiliated with the University of British Columbia, where he conducts his research and develops his innovative ideas. His work has garnered attention for its potential to improve cancer treatment outcomes.
Collaborations
Some of his notable coworkers include Martin E. Gleave and Paul Rennie, who have collaborated with him on various research projects.
Conclusion
Hikeaki Miyake's contributions to cancer treatment through his innovative patent demonstrate his commitment to advancing medical science. His work has the potential to significantly improve the lives of cancer patients by enhancing the effectiveness of existing treatments.